Eli Lilly has struck a deal to buy the near-global rights to a P2X7 receptor antagonist from Asahi Kasei Pharma. The agreement will give Lilly control of a treatment for neuroinflammatory pain conditions that recently completed phase 1 studies.
INDIANAPOLIS and TOKYO, Jan. 28, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma. AK1780 is an orally bioavailable P2X7 receptor antagonist that recently completed Phase 1 single and multiple ascending dose and clinical pharmacology studies. P2X7 receptors have been consistently implicated in neuroinflammation, a driving force in chronic pain conditions.
Asahi Kasei (3407.T) has offered 8.9 billion Danish crowns ($1.31 billion) to buy Veloxis (VELOX.CO), it said on Monday, a deal that would give the Japanese electronic materials maker access to the U.S. pharmaceutical market.
This report analyzes and forecasts the market for excipients at the global and regional level. The market has been forecast based on volume (tons) and revenue (US$ Thousand) from 2015 to 2023. The study includes drivers and restraints of the global excipients market. It also covers the impact of these drivers and restraints on demand for excipients during the forecast period. The report also highlights opportunities in the excipients market at the global and regional level.
The global microcrystalline cellulose (MCC) market is moderately fragmented owing to the presence of a large number of players, states Transparency Market Research in its new study. Key players operating in the global microcrystalline cellulose market are focusing on expansion strategies. Thus, many players are entering into agreements, partnerships, collaborations, and mergers to strengthen their position in the market. Some of the key players operating in the MCC market are Mingtai Chemical Co., Ltd., Asahi Kasei Corporation, J. Rettenmaier & Soehne GmbH + Co KG, Blanver Farmoquimica LTDA, Accent Microcell Pvt. Ltd., FMC Corporation, Juku Orchem Private Limited, DFE Pharma GmbH & Co. KG, Libraw Pharma, Sigachi Industrial Pvt. Ltd., and Avantor Performance Materials, Inc.
Cellulose is the prime component of plant cell. Microcrystalline cellulose is partially depolymerized cellulose, obtained from wood pulp. It is also formed through some of the fungi, bacteria, algae or marine animals. It is insoluble in water and is primarily used as bulking and anticaking agent in production of food products. It is also used as a texturizer, emulsifier and as an extender in application such as pharmaceutical or personal care products. Wide usage of microcrystalline cellulose in manufacturing food products coupled with growing of the pharmaceutical excipient industry is driving the demand of microcrystalline cellulose market across the globe.
Array BioPharma Inc. (Nasdaq: ARRY) and Asahi Kasei Pharma Corporation today announced a strategic collaboration to develop and commercialize select Tropomyosin receptor kinase A (TrkA) inhibitors, including Array-invented ARRY-954, for pain, inflammation and other non-cancer indications. Array retains the right for all compounds for all indications outside of Asia. Within Asia, Array retains the right to cancer indications for all compounds, excluding those compounds being developed by Asahi Kasei Pharma, including ARRY-954.
Japan's Agency for Medical Research and Development (AMED) named 8 projects for a pre-designation review as orphan drug commercialization candidates. These include three candidates from Tokyo-based Nobelpharma: N-acetylneuraminic acid for distal myopathy; NPC-14 (arbekacin sulfate) for Duchenne muscular dystrophy and a malaria vaccine. Candidates from other